Natural Products Research Division, Department of Biological and Biomedical Sciences, Aga Khan University Medical College, Karachi 74800, Pakistan.
J Nat Med. 2012 Jan;66(1):119-26. doi: 10.1007/s11418-011-0561-7. Epub 2011 Aug 9.
This investigation was aimed to probe the pharmacological base of medicinal use of Acorus calamus in ischemic heart diseases. Effect on heart parameters was studied in isolated rabbit heart while coronary vasodilator effect was studied in isolated bovine coronary arterial rings, suspended in tissue baths filled with Krebs solution, maintained at 37°C, aerated with carbogen and responses were measured on PowerLab data acquisition system. In Langendorrf's perfused rabbit heart, the crude extract of Acorus calamus (Ac.Cr) at 0.01-10 mg/mL partially suppressed force of ventricular contractions (FVC), heart rate (HR) and coronary flow (CF). The ethylacetate fraction completely suppressed FVC, partially suppressed HR and CF, while the nHexane fraction exhibited similar effect on FVC and HR but increased CF, similar to methacholine and arachidonic acid. In bovine coronary arterial preparations, Ac.Cr caused inhibition of U46619 (20 nM)-precontractions, which was blocked in presence of increasing concentration of K(+) (4.8-20 mM), tetraethylammonium (1 μM) and SKF525A (10 μM), similar to arachidonic acid and methacholine, indicating K(+) channels activation and possible involvement of endothelial-derived hyperpolarizing factor (EDHF). Activity-directed fractionation revealed that EDHF-mediated activity is concentrated in the nHexane fraction. When tested against high K(+), the ethylacetate fraction was found more potent than parent crude extract and nHexane fraction. These data indicate that Ac.Cr mediates coronary vasodilator effect primarily through EDHF, responsible for the increase in CF, while the cardiac depressant effects may be due to the presence of additional cardiac depressant constituent(s), thus provides possible mechanistic basis to its medicinal use in ischemic heart diseases.
这项研究旨在探究菖蒲在缺血性心脏病中的药用价值的药理学基础。在离体兔心中研究了心脏参数的影响,在悬浮于充满 Krebs 溶液的组织浴中的离体牛冠状动脉环中研究了冠状血管扩张作用,保持在 37°C,用碳化氧充气,并在 PowerLab 数据采集系统上测量反应。在 Langendorff 灌注的兔心中,菖蒲的粗提取物(Ac.Cr)在 0.01-10mg/ml 时部分抑制心室收缩力(FVC)、心率(HR)和冠状血流(CF)。乙酸乙酯部分完全抑制 FVC,部分抑制 HR 和 CF,而正己烷部分对 FVC 和 HR 表现出相似的作用,但增加 CF,类似于甲酰胆碱和花生四烯酸。在牛冠状动脉制剂中,Ac.Cr 抑制 U46619(20nm)预收缩,在增加浓度的钾(+)(4.8-20mm)、四乙铵(1μM)和 SKF525A(10μM)存在下,这种抑制作用被阻断,类似于花生四烯酸和甲酰胆碱,表明钾(+)通道激活和内皮衍生超极化因子(EDHF)的可能参与。活性导向的分步分离表明,EDHF 介导的活性集中在正己烷部分。当与高钾(+)测试时,发现乙酸乙酯部分比母体粗提取物和正己烷部分更有效。这些数据表明,Ac.Cr 主要通过 EDHF 介导冠状血管扩张作用,导致 CF 增加,而心脏抑制作用可能是由于存在其他心脏抑制成分,从而为其在缺血性心脏病中的药用价值提供了可能的机制基础。